Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 217 to 227 of 227 entries
Sorted by: Best Match Show Resources per page
Targeting p21.

Cell metabolism

Wang L, Wang B, Gasek NS, Zhou Y, Cohn RL, Martin DE, Zuo W, Flynn WF, Guo C, Jellison ER, Kim T, Langhi Prata LGP, Palmer AK, Li M, Inman CL, Barber LS, Al-Naggar IMA, Zhou Y, Du W, Kshitiz, Kuchel GA, Meves A, Tchkonia T, Kirkland JL, Robson P, Xu M.
PMID: 34986334
Cell Metab. 2022 Jan 04;34(1):186. doi: 10.1016/j.cmet.2021.12.014.

No abstract available.

Cite
Wang L, Wang B, Gasek NS, et al. Targeting p21. Cell Metab. 2022;34(1):186doi: 10.1016/j.cmet.2021.12.014.
Wang, L., Wang, B., Gasek, N. S., Zhou, Y., Cohn, R. L., Martin, D. E., Zuo, W., Flynn, W. F., Guo, C., Jellison, E. R., Kim, T., Langhi Prata, L. G. P., Palmer, A. K., Li, M., Inman, C. L., Barber, L. S., Al-Naggar, I. M. A., Zhou, Y., Du, W., Kshitiz, Kuchel, G. A., Meves, A., Tchkonia, T., Kirkland, J. L., Robson, P., & Xu, M. (2022). Targeting p21. Cell metabolism, 34(1), 186. https://doi.org/10.1016/j.cmet.2021.12.014
Wang, Lichao, et al. "Targeting p21." Cell metabolism vol. 34,1 (2022): 186. doi: https://doi.org/10.1016/j.cmet.2021.12.014
Wang L, Wang B, Gasek NS, Zhou Y, Cohn RL, Martin DE, Zuo W, Flynn WF, Guo C, Jellison ER, Kim T, Langhi Prata LGP, Palmer AK, Li M, Inman CL, Barber LS, Al-Naggar IMA, Zhou Y, Du W, Kshitiz, Kuchel GA, Meves A, Tchkonia T, Kirkland JL, Robson P, Xu M. Targeting p21. Cell Metab. 2022 Jan 04;34(1):186. doi: 10.1016/j.cmet.2021.12.014. PMID: 34986334.
Copy Download .nbib Format: NLM
Targeting p21.

Cell metabolism

Wang L, Wang B, Gasek NS, Zhou Y, Cohn RL, Martin DE, Zuo W, Flynn WF, Guo C, Jellison ER, Kim T, Prata LGPL, Palmer AK, Li M, Inman CL, Barber LS, Al-Naggar IMA, Zhou Y, Du W, Kshitiz, Kuchel GA, Meves A, Tchkonia T, Kirkland JL, Robson P, Xu M.
PMID: 34813734
Cell Metab. 2022 Jan 04;34(1):75-89.e8. doi: 10.1016/j.cmet.2021.11.002. Epub 2021 Nov 22.

Insulin resistance is a pathological state often associated with obesity, representing a major risk factor for type 2 diabetes. Limited mechanism-based strategies exist to alleviate insulin resistance. Here, using single-cell transcriptomics, we identify a small, critically important, but previously...

Cite
Wang L, Wang B, Gasek NS, et al. Targeting p21. Cell Metab. 2021;34(1):75-89.e8doi: 10.1016/j.cmet.2021.11.002.
Wang, L., Wang, B., Gasek, N. S., Zhou, Y., Cohn, R. L., Martin, D. E., Zuo, W., Flynn, W. F., Guo, C., Jellison, E. R., Kim, T., Prata, L. G. P. L., Palmer, A. K., Li, M., Inman, C. L., Barber, L. S., Al-Naggar, I. M. A., Zhou, Y., Du, W., Kshitiz, Kuchel, G. A., Meves, A., Tchkonia, T., Kirkland, J. L., Robson, P., & Xu, M. (2022). Targeting p21. Cell metabolism, 34(1), 75-89.e8. https://doi.org/10.1016/j.cmet.2021.11.002
Wang, Lichao, et al. "Targeting p21." Cell metabolism vol. 34,1 (2022): 75-89.e8. doi: https://doi.org/10.1016/j.cmet.2021.11.002
Wang L, Wang B, Gasek NS, Zhou Y, Cohn RL, Martin DE, Zuo W, Flynn WF, Guo C, Jellison ER, Kim T, Prata LGPL, Palmer AK, Li M, Inman CL, Barber LS, Al-Naggar IMA, Zhou Y, Du W, Kshitiz, Kuchel GA, Meves A, Tchkonia T, Kirkland JL, Robson P, Xu M. Targeting p21. Cell Metab. 2022 Jan 04;34(1):75-89.e8. doi: 10.1016/j.cmet.2021.11.002. Epub 2021 Nov 22. PMID: 34813734; PMCID: PMC8732323.
Copy Download .nbib Format: NLM
Targeting p21.

Cell metabolism

Wang L, Wang B, Gasek NS, Zhou Y, Cohn RL, Martin DE, Zuo W, Flynn WF, Guo C, Jellison ER, Kim T, Prata LGPL, Palmer AK, Li M, Inman CL, Barber LS, Al-Naggar IMA, Zhou Y, Kuchel GA, Meves A, Tchkonia T, Kirkland JL, Robson P, Xu M.
PMID: 34813734
Cell Metab. 2021 Nov 19; doi: 10.1016/j.cmet.2021.11.002. Epub 2021 Nov 19.

Insulin resistance is a pathological state often associated with obesity, representing a major risk factor for type 2 diabetes. Limited mechanism-based strategies exist to alleviate insulin resistance. Here, using single-cell transcriptomics, we identify a small, critically important, but previously...

Cite
Wang L, Wang B, Gasek NS, et al. Targeting p21. Cell Metab. 2021;doi: 10.1016/j.cmet.2021.11.002.
Wang, L., Wang, B., Gasek, N. S., Zhou, Y., Cohn, R. L., Martin, D. E., Zuo, W., Flynn, W. F., Guo, C., Jellison, E. R., Kim, T., Prata, L. G. P. L., Palmer, A. K., Li, M., Inman, C. L., Barber, L. S., Al-Naggar, I. M. A., Zhou, Y., Kuchel, G. A., Meves, A., Tchkonia, T., Kirkland, J. L., Robson, P., & Xu, M. (2021). Targeting p21. Cell metabolism, . https://doi.org/10.1016/j.cmet.2021.11.002
Wang, Lichao, et al. "Targeting p21." Cell metabolism vol. (2021). doi: https://doi.org/10.1016/j.cmet.2021.11.002
Wang L, Wang B, Gasek NS, Zhou Y, Cohn RL, Martin DE, Zuo W, Flynn WF, Guo C, Jellison ER, Kim T, Prata LGPL, Palmer AK, Li M, Inman CL, Barber LS, Al-Naggar IMA, Zhou Y, Kuchel GA, Meves A, Tchkonia T, Kirkland JL, Robson P, Xu M. Targeting p21. Cell Metab. 2021 Nov 19; doi: 10.1016/j.cmet.2021.11.002. Epub 2021 Nov 19. PMID: 34813734.
Copy Download .nbib Format: NLM
Computer-Assisted Qualitative Data Analysis Software, Phenomenology, and Colaizzi's Method.

Western journal of nursing research

Vignato J, Inman M, Patsais M, Conley V.
PMID: 34238074
West J Nurs Res. 2021 Jul 08;1939459211030335. doi: 10.1177/01939459211030335. Epub 2021 Jul 08.

Technology is widely used to support qualitative research. Computer-Assisted Qualitative Data Analysis Software (CAQDAS) encompasses complementary technologies to support qualitative analysis. Advantages of CAQDAS include efficient management of data and transparency in analysis. Disadvantages include heavy emphasis on coding...

Cite
Vignato J, Inman M, Patsais M, et al. Computer-Assisted Qualitative Data Analysis Software, Phenomenology, and Colaizzi's Method. West J Nurs Res. 2021;1939459211030335doi: 10.1177/01939459211030335.
Vignato, J., Inman, M., Patsais, M., & Conley, V. (2021). Computer-Assisted Qualitative Data Analysis Software, Phenomenology, and Colaizzi's Method. Western journal of nursing research, 1939459211030335. https://doi.org/10.1177/01939459211030335
Vignato, Julie, et al. "Computer-Assisted Qualitative Data Analysis Software, Phenomenology, and Colaizzi's Method." Western journal of nursing research vol. (2021): 1939459211030335. doi: https://doi.org/10.1177/01939459211030335
Vignato J, Inman M, Patsais M, Conley V. Computer-Assisted Qualitative Data Analysis Software, Phenomenology, and Colaizzi's Method. West J Nurs Res. 2021 Jul 08;1939459211030335. doi: 10.1177/01939459211030335. Epub 2021 Jul 08. PMID: 34238074.
Copy Download .nbib Format: NLM
Self-silencing Mediates the Relationship Between Rejection Sensitivity and Intimate Partner Violence.

Journal of interpersonal violence

Inman EM, London B.
PMID: 33703956
J Interpers Violence. 2021 Mar 11;886260521997948. doi: 10.1177/0886260521997948. Epub 2021 Mar 11.

Intimate partner violence, including physical, psychological, and sexual violence, affects over one-third of Americans and is particularly common among college students. Previous work has found links between rejection sensitivity and aggressive or hostile behavior (i.e., perpetration) in intimate relationships,...

Cite
Inman EM, London B. Self-silencing Mediates the Relationship Between Rejection Sensitivity and Intimate Partner Violence. J Interpers Violence. 2021;886260521997948doi: 10.1177/0886260521997948.
Inman, E. M., & London, B. (2021). Self-silencing Mediates the Relationship Between Rejection Sensitivity and Intimate Partner Violence. Journal of interpersonal violence, 886260521997948. https://doi.org/10.1177/0886260521997948
Inman, Elizabeth M, and London, Bonita. "Self-silencing Mediates the Relationship Between Rejection Sensitivity and Intimate Partner Violence." Journal of interpersonal violence vol. (2021): 886260521997948. doi: https://doi.org/10.1177/0886260521997948
Inman EM, London B. Self-silencing Mediates the Relationship Between Rejection Sensitivity and Intimate Partner Violence. J Interpers Violence. 2021 Mar 11;886260521997948. doi: 10.1177/0886260521997948. Epub 2021 Mar 11. PMID: 33703956.
Copy Download .nbib Format: NLM
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.

European urology

Mitra AP, Narayan VM, Mokkapati S, Miest T, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown GA, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Philipson R, Ylä-Herttuala S, Sawutz D, Parker NR, McConkey DJ, Dinney CPN.
PMID: 34933753
Eur Urol. 2021 Dec 18; doi: 10.1016/j.eururo.2021.12.009. Epub 2021 Dec 18.

A recent phase 3 trial of intravesical nadofaragene firadenovec reported a promising complete response rate for patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer. This study examined the ability of antiadenovirus antibody levels to predict the durability of therapeutic response...

Cite
Mitra AP, Narayan VM, Mokkapati S, et al. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2021;doi: 10.1016/j.eururo.2021.12.009.
Mitra, A. P., Narayan, V. M., Mokkapati, S., Miest, T., Boorjian, S. A., Alemozaffar, M., Konety, B. R., Shore, N. D., Gomella, L. G., Kamat, A. M., Bivalacqua, T. J., Montgomery, J. S., Lerner, S. P., Busby, J. E., Poch, M., Crispen, P. L., Steinberg, G. D., Schuckman, A. K., Downs, T. M., Svatek, R. S., Mashni, J., Lane, B. R., Guzzo, T. J., Bratslavsky, G., Karsh, L. I., Woods, M. E., Brown, G. A., Canter, D., Luchey, A., Lotan, Y., Krupski, T., Inman, B. A., Williams, M. B., Cookson, M. S., Keegan, K. A., Andriole, G. L., Sankin, A. I., Boyd, A., O'Donnell, M. A., Philipson, R., Ylä-Herttuala, S., Sawutz, D., Parker, N. R., McConkey, D. J., & Dinney, C. P. N. (2021). Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. European urology, . https://doi.org/10.1016/j.eururo.2021.12.009
Mitra, Anirban P, et al. "Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial." European urology vol. (2021). doi: https://doi.org/10.1016/j.eururo.2021.12.009
Mitra AP, Narayan VM, Mokkapati S, Miest T, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown GA, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Philipson R, Ylä-Herttuala S, Sawutz D, Parker NR, McConkey DJ, Dinney CPN. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2021 Dec 18; doi: 10.1016/j.eururo.2021.12.009. Epub 2021 Dec 18. PMID: 34933753.
Copy Download .nbib Format: NLM
Familial nephropathy in Bracchi Italiani: 8 cases (2012-2019).

Journal of the American Veterinary Medical Association

Inman AL, Allen-Durrance AE, Cianciolo RE, Harris AN.
PMID: 34757934
J Am Vet Med Assoc. 2021 Dec 15;1-6. doi: 10.2460/javma.20.07.0420. Epub 2021 Dec 15.

OBJECTIVE: To characterize the signalment, clinical signs, clinical pathological and histologic findings, and outcome in 8 related Bracchi Italiani with proteinuric kidney disease.ANIMALS: 8 client-owned Bracchi Italiani.PROCEDURES: Health records submitted to the Bracco Italiano Health Foundation and the Bracco...

Cite
Inman AL, Allen-Durrance AE, Cianciolo RE, et al. Familial nephropathy in Bracchi Italiani: 8 cases (2012-2019). J Am Vet Med Assoc. 2021;1-6doi: 10.2460/javma.20.07.0420.
Inman, A. L., Allen-Durrance, A. E., Cianciolo, R. E., & Harris, A. N. (2021). Familial nephropathy in Bracchi Italiani: 8 cases (2012-2019). Journal of the American Veterinary Medical Association, 1-6. https://doi.org/10.2460/javma.20.07.0420
Inman, Amanda L, et al. "Familial nephropathy in Bracchi Italiani: 8 cases (2012-2019)." Journal of the American Veterinary Medical Association vol. (2021): 1-6. doi: https://doi.org/10.2460/javma.20.07.0420
Inman AL, Allen-Durrance AE, Cianciolo RE, Harris AN. Familial nephropathy in Bracchi Italiani: 8 cases (2012-2019). J Am Vet Med Assoc. 2021 Dec 15;1-6. doi: 10.2460/javma.20.07.0420. Epub 2021 Dec 15. PMID: 34757934.
Copy Download .nbib Format: NLM
Safety and Efficacy of Bariatric Surgery in Cirrhosis Patients With Extreme Obesity.

Annals of surgery

Vuppalanchi R, McCabe ME, Tandra SR, Parcha SP, Ghafoor A, Schuh L, Inman MM, Selzer DJ, Stefanidis D, Chalasani N.
PMID: 32925171
Ann Surg. 2022 Jan 01;275(1):e174-e180. doi: 10.1097/SLA.0000000000003891.

OBJECTIVE: To assess the safety and efficacy of bariatric surgery in patients with cirrhosis.SUMMARY BACKGROUND DATA: Bariatric surgery may be a viable option for patients with cirrhosis and extreme obesity. However, the risk of liver decompensation after surgery is...

Cite
Vuppalanchi R, McCabe ME, Tandra SR, et al. Safety and Efficacy of Bariatric Surgery in Cirrhosis Patients With Extreme Obesity. Ann Surg. 2022;275(1):e174-e180doi: 10.1097/SLA.0000000000003891.
Vuppalanchi, R., McCabe, M. E., Tandra, S. R., Parcha, S. P., Ghafoor, A., Schuh, L., Inman, M. M., Selzer, D. J., Stefanidis, D., & Chalasani, N. (2022). Safety and Efficacy of Bariatric Surgery in Cirrhosis Patients With Extreme Obesity. Annals of surgery, 275(1), e174-e180. https://doi.org/10.1097/SLA.0000000000003891
Vuppalanchi, Raj, et al. "Safety and Efficacy of Bariatric Surgery in Cirrhosis Patients With Extreme Obesity." Annals of surgery vol. 275,1 (2022): e174-e180. doi: https://doi.org/10.1097/SLA.0000000000003891
Vuppalanchi R, McCabe ME, Tandra SR, Parcha SP, Ghafoor A, Schuh L, Inman MM, Selzer DJ, Stefanidis D, Chalasani N. Safety and Efficacy of Bariatric Surgery in Cirrhosis Patients With Extreme Obesity. Ann Surg. 2022 Jan 01;275(1):e174-e180. doi: 10.1097/SLA.0000000000003891. PMID: 32925171.
Copy Download .nbib Format: NLM
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.

Clinical cancer research : an official journal of the American Association for Cancer Research

Adib E, Klonowska K, Giannikou K, Do KT, Pruitt-Thompson S, Bhushan K, Milstein MI, Hedglin J, Kargus KE, Sholl LM, Tsuji J, Hyman DM, Sisk A, Shapiro GI, Vargas HA, Harding JJ, Voss MH, Iyer G, Kwiatkowski DJ.
PMID: 33727259
Clin Cancer Res. 2021 Jul 15;27(14):3845-3853. doi: 10.1158/1078-0432.CCR-20-4548. Epub 2021 Mar 16.

PURPOSE: This was a multicenter, histology-agnostic, single-arm prospective phase II trial of therapeutic activity of everolimus, an oral mTORC1 inhibitor, in patients with advanced solid tumors that harbored PATIENTS AND METHODS: Patients with tumors with inactivating RESULTS: Between November...

Cite
Adib E, Klonowska K, Giannikou K, et al. Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. Clin Cancer Res. 2021;27(14):3845-3853doi: 10.1158/1078-0432.CCR-20-4548.
Adib, E., Klonowska, K., Giannikou, K., Do, K. T., Pruitt-Thompson, S., Bhushan, K., Milstein, M. I., Hedglin, J., Kargus, K. E., Sholl, L. M., Tsuji, J., Hyman, D. M., Sisk, A., Shapiro, G. I., Vargas, H. A., Harding, J. J., Voss, M. H., Iyer, G., & Kwiatkowski, D. J. (2021). Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(14), 3845-3853. https://doi.org/10.1158/1078-0432.CCR-20-4548
Adib, Elio, et al. "Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,14 (2021): 3845-3853. doi: https://doi.org/10.1158/1078-0432.CCR-20-4548
Adib E, Klonowska K, Giannikou K, Do KT, Pruitt-Thompson S, Bhushan K, Milstein MI, Hedglin J, Kargus KE, Sholl LM, Tsuji J, Hyman DM, Sisk A, Shapiro GI, Vargas HA, Harding JJ, Voss MH, Iyer G, Kwiatkowski DJ. Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. Clin Cancer Res. 2021 Jul 15;27(14):3845-3853. doi: 10.1158/1078-0432.CCR-20-4548. Epub 2021 Mar 16. PMID: 33727259; PMCID: PMC8282751.
Copy Download .nbib Format: NLM
Building bridges between drug development and cancer science: a tribute to José Baselga's legacy.

Annals of oncology : official journal of the European Society for Medical Oncology

Hyman DM, Soria JC, Tabernero J.
PMID: 33838220
Ann Oncol. 2021 Jul;32(7):825-828. doi: 10.1016/j.annonc.2021.03.209. Epub 2021 Apr 07.

No abstract available.

Cite
Hyman DM, Soria JC, Tabernero J. Building bridges between drug development and cancer science: a tribute to José Baselga's legacy. Ann Oncol. 2021;32(7):825-828doi: 10.1016/j.annonc.2021.03.209.
Hyman, D. M., Soria, J. C., & Tabernero, J. (2021). Building bridges between drug development and cancer science: a tribute to José Baselga's legacy. Annals of oncology : official journal of the European Society for Medical Oncology, 32(7), 825-828. https://doi.org/10.1016/j.annonc.2021.03.209
Hyman, D M, et al. "Building bridges between drug development and cancer science: a tribute to José Baselga's legacy." Annals of oncology : official journal of the European Society for Medical Oncology vol. 32,7 (2021): 825-828. doi: https://doi.org/10.1016/j.annonc.2021.03.209
Hyman DM, Soria JC, Tabernero J. Building bridges between drug development and cancer science: a tribute to José Baselga's legacy. Ann Oncol. 2021 Jul;32(7):825-828. doi: 10.1016/j.annonc.2021.03.209. Epub 2021 Apr 07. PMID: 33838220.
Copy Download .nbib Format: NLM
Familial nephropathy in Bracchi Italiani: 8 cases (2012-2019).

Journal of the American Veterinary Medical Association

Inman AL, Allen-Durrance AE, Cianciolo RE, Harris AN.
PMID: 34757934
J Am Vet Med Assoc. 2021 Nov 10;259(12):1422-1427. doi: 10.2460/javma.20.07.0420.

OBJECTIVE: To characterize the signalment, clinical signs, clinical pathological and histologic findings, and outcome in 8 related Bracchi Italiani with proteinuric kidney disease.ANIMALS: 8 client-owned Bracchi Italiani.PROCEDURES: Health records submitted to the Bracco Italiano Health Foundation and the Bracco...

Cite
Inman AL, Allen-Durrance AE, Cianciolo RE, et al. Familial nephropathy in Bracchi Italiani: 8 cases (2012-2019). J Am Vet Med Assoc. 2021;259(12):1422-1427doi: 10.2460/javma.20.07.0420.
Inman, A. L., Allen-Durrance, A. E., Cianciolo, R. E., & Harris, A. N. (2021). Familial nephropathy in Bracchi Italiani: 8 cases (2012-2019). Journal of the American Veterinary Medical Association, 259(12), 1422-1427. https://doi.org/10.2460/javma.20.07.0420
Inman, Amanda L, et al. "Familial nephropathy in Bracchi Italiani: 8 cases (2012-2019)." Journal of the American Veterinary Medical Association vol. 259,12 (2021): 1422-1427. doi: https://doi.org/10.2460/javma.20.07.0420
Inman AL, Allen-Durrance AE, Cianciolo RE, Harris AN. Familial nephropathy in Bracchi Italiani: 8 cases (2012-2019). J Am Vet Med Assoc. 2021 Nov 10;259(12):1422-1427. doi: 10.2460/javma.20.07.0420. PMID: 34757934.
Copy Download .nbib Format: NLM
Showing 217 to 227 of 227 entries